FAK-IN-16

FAK-IN-16 (compound OXA-11) is an orally active, selective focal adhesion kinase (FAK) inhibitor with an IC50 of 1.2 pM. FAK-IN-16 inhibits FAK phosphorylation at pFAK[Y397] and pFAK[Y861]. FAK-IN-16 slows tumor growth and reduces tumor vascularity, invasion. FAK-IN-16 potentiates effects of Cisplatin (HY-17394) on tumor cell proliferation and apoptosis in vitro and anti-tumor actions in mice[1].

Product Specifications

CAS Number

[1257994-15-2]

UNSPSC

12352005

Target

FAK

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fak-in-16.html

Solubility

10 mM in DMSO

Smiles

COC1=CC(CP(OCC)(OCC)=O)=CC=C1NC2=NC=C(C(F)(F)F)C(NC3=CC=C([C@H]4CC[C@H](N5CCN(C)CC5)CC4)C(CN6C)=C3C6=O)=N2

Molecular Formula

C37H49F3N7O5P

Molecular Weight

759.80

References & Citations

[1]Ingrid Moen, et al. Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. Clin Exp Metastasis. 2015 Dec;32 (8) :799-817.